Open Access
Molecular Cancer, volume 19, issue 1, publication number 79
Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy
Yuanjun Lu
1
,
Yau‐Tuen Chan
1
,
Hor-Yue Tan
1
,
Sha Li
1
,
Ning Wang
1
,
Yibin Feng
1
Publication type: Journal Article
Publication date: 2020-04-27
Journal:
Molecular Cancer
scimago Q1
wos Q1
SJR: 8.222
CiteScore: 54.9
Impact factor: 27.7
ISSN: 14764598
Cancer Research
Oncology
Molecular Medicine
Abstract
Epigenetics is dynamic and heritable modifications to the genome that occur independently of DNA sequence. It requires interactions cohesively with various enzymes and other molecular components. Aberrant epigenetic alterations can lead to inappropriate onset of genetic expressions and promote tumorigenesis. As the epigenetic modifiers are susceptible to extrinsic factors and reversible, they are becoming promising targets in multiple cancer therapies. Recently, various epi-drugs have been developed and implicated in clinical use. The use of epi-drugs alone, or in combination with chemotherapy or immunotherapy, has shown compelling outcomes, including augmentation of anti-tumoral effects, overcoming drug resistance, and activation of host immune response.
Found
Top-30
Journals
2
4
6
8
10
12
14
16
18
|
|
International Journal of Molecular Sciences
17 publications, 5.45%
|
|
Cancers
13 publications, 4.17%
|
|
Epigenomes
7 publications, 2.24%
|
|
Seminars in Cancer Biology
6 publications, 1.92%
|
|
Frontiers in Oncology
5 publications, 1.6%
|
|
International Review of Cell and Molecular Biology
5 publications, 1.6%
|
|
Frontiers in Cell and Developmental Biology
4 publications, 1.28%
|
|
Biochimica et Biophysica Acta - Reviews on Cancer
4 publications, 1.28%
|
|
Interdisciplinary Cancer Research
4 publications, 1.28%
|
|
Pathology Research and Practice
4 publications, 1.28%
|
|
Cells
3 publications, 0.96%
|
|
Journal of Clinical Medicine
3 publications, 0.96%
|
|
Frontiers in Genetics
3 publications, 0.96%
|
|
Journal of Experimental and Clinical Cancer Research
3 publications, 0.96%
|
|
Pharmacology and Therapeutics
3 publications, 0.96%
|
|
Cancer Letters
3 publications, 0.96%
|
|
Molecular Cancer
3 publications, 0.96%
|
|
Journal of Biomolecular Structure and Dynamics
3 publications, 0.96%
|
|
Bioorganic Chemistry
3 publications, 0.96%
|
|
Clinical Epigenetics
3 publications, 0.96%
|
|
Heliyon
3 publications, 0.96%
|
|
Advances in molecular oncology
2 publications, 0.64%
|
|
Current Cancer Drug Targets
2 publications, 0.64%
|
|
Genes
2 publications, 0.64%
|
|
Frontiers in Pharmacology
2 publications, 0.64%
|
|
Biomedicines
2 publications, 0.64%
|
|
Cancer Cell International
2 publications, 0.64%
|
|
Scientific Reports
2 publications, 0.64%
|
|
Medicinal Research Reviews
2 publications, 0.64%
|
|
2
4
6
8
10
12
14
16
18
|
Publishers
10
20
30
40
50
60
70
80
90
|
|
Elsevier
86 publications, 27.56%
|
|
MDPI
57 publications, 18.27%
|
|
Springer Nature
54 publications, 17.31%
|
|
Frontiers Media S.A.
20 publications, 6.41%
|
|
Wiley
18 publications, 5.77%
|
|
Taylor & Francis
15 publications, 4.81%
|
|
Bentham Science Publishers Ltd.
7 publications, 2.24%
|
|
Spandidos Publications
4 publications, 1.28%
|
|
Cold Spring Harbor Laboratory
4 publications, 1.28%
|
|
Mary Ann Liebert
3 publications, 0.96%
|
|
Oxford University Press
3 publications, 0.96%
|
|
IntechOpen
3 publications, 0.96%
|
|
Publishing House ABV Press
2 publications, 0.64%
|
|
Walter de Gruyter
2 publications, 0.64%
|
|
Public Library of Science (PLoS)
2 publications, 0.64%
|
|
Royal Society of Chemistry (RSC)
2 publications, 0.64%
|
|
AME Publishing Company
2 publications, 0.64%
|
|
Ovid Technologies (Wolters Kluwer Health)
1 publication, 0.32%
|
|
Moffitt Cancer Center
1 publication, 0.32%
|
|
American Society for Microbiology
1 publication, 0.32%
|
|
MJS Publishing, Medical Journals Sweden AB
1 publication, 0.32%
|
|
The Company of Biologists
1 publication, 0.32%
|
|
BMJ
1 publication, 0.32%
|
|
Hindawi Limited
1 publication, 0.32%
|
|
American Society of Hematology
1 publication, 0.32%
|
|
American Society of Clinical Oncology (ASCO)
1 publication, 0.32%
|
|
American Association for the Advancement of Science (AAAS)
1 publication, 0.32%
|
|
Tomsk Cancer Research Institute
1 publication, 0.32%
|
|
IRBIS
1 publication, 0.32%
|
|
10
20
30
40
50
60
70
80
90
|
- We do not take into account publications without a DOI.
- Statistics recalculated only for publications connected to researchers, organizations and labs registered on the platform.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Cite this
GOST |
RIS |
BibTex
Cite this
GOST
Copy
Lu Y. et al. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy // Molecular Cancer. 2020. Vol. 19. No. 1. 79
GOST all authors (up to 50)
Copy
Lu Y., Chan Y., Tan H., Li S., Wang N., Feng Y. Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy // Molecular Cancer. 2020. Vol. 19. No. 1. 79
Cite this
RIS
Copy
TY - JOUR
DO - 10.1186/s12943-020-01197-3
UR - https://doi.org/10.1186/s12943-020-01197-3
TI - Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy
T2 - Molecular Cancer
AU - Lu, Yuanjun
AU - Chan, Yau‐Tuen
AU - Tan, Hor-Yue
AU - Li, Sha
AU - Wang, Ning
AU - Feng, Yibin
PY - 2020
DA - 2020/04/27
PB - Springer Nature
IS - 1
VL - 19
SN - 1476-4598
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2020_Lu,
author = {Yuanjun Lu and Yau‐Tuen Chan and Hor-Yue Tan and Sha Li and Ning Wang and Yibin Feng},
title = {Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy},
journal = {Molecular Cancer},
year = {2020},
volume = {19},
publisher = {Springer Nature},
month = {apr},
url = {https://doi.org/10.1186/s12943-020-01197-3},
number = {1},
doi = {10.1186/s12943-020-01197-3}
}
Found error?
Found error?
Publisher
Journal
scimago Q1
wos Q1
SJR
8.222
CiteScore
54.9
Impact factor
27.7
ISSN
14764598
(Electronic)